title: Atypical central neurocytoma.
abstract: The proliferative potential of central neurocytomas was determined in a biopsy series of 36 cases and compared with clinical outcome. The mean size of the growth fraction, as determined by MIB-1 labeling index (MIB-1 LI) at first biopsy, was 2.8 +/- 2.5 with a range of 0.1 to 8.6%. Neurocytomas with an MIB-1 LI > 2% comprised 39% of cases and showed a close correlation with the presence of vascular proliferation (p = 0.0006). The Kaplan-Meier analysis showed a highly significant difference in disease-free survival between the 2 groups (p = 0.0068). Over an observation time of 150 months, there was a 22% relapse among patients with an MIB-1 LI less than 2% and a 63% chance of relapse among those with an MIB-1 LI greater than 2%. We propose the term "atypical central neurocytoma" for the latter subset, corresponding to WHO grade II.
authors.affiliation: Department of Pathology, University Hospital, Zürich, Switzerland.
authors.forename: F
authors.initials: F
authors.lastname: Söylemezoglu
authors.forename: B W
authors.initials: BW
authors.lastname: Scheithauer
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: P
authors.initials: P
authors.lastname: Kleihues
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002551:Cerebral Ventricle Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D002648:Child; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009389:Neovascularization, Pathologic / Q000473:pathology; D018306:Neurocytoma / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D016019:Survival Analysis